SCHEMBL504484

SCHEMBL504484

N#CN/C(=N/c1ccncc1)NCCCCCCC(=O)c1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
NAMPT P43490 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
HDAC1 Q13547 3/20 0.40
HDAC3 O15379 2/20 0.40
HDAC4 P56524 2/20 0.40
HDAC7 Q8WUI4 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC9 Q9UKV0 2/20 0.40
HDAC5 Q9UQL6 2/20 0.40
CYP1A2 P05177 1/20 0.39
IKBKB O14920 1/20 0.38
HRH4 Q9H3N8 1/20 0.37
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL504485 1.00 CYP2C9 (0.40) CYP2C9CYP2C19NAMPTCYP3A4CYP2D6
SCHEMBL504473 1.00 CYP2C9 (0.40) CYP2C9CYP2C19NAMPTCYP3A4CYP2D6
SCHEMBL504474 1.00 CYP2C9 (0.40) CYP2C9CYP2C19NAMPTCYP3A4CYP2D6
SCHEMBL504928 1.00 CYP2C9 (0.40) CYP2C9CYP2C19NAMPTCYP3A4CYP2D6
SCHEMBL504929 1.00 CYP2C9 (0.40) CYP2C9CYP2C19NAMPTCYP3A4CYP2D6
SCHEMBL504314 0.89 HDAC3 (0.46) CYP2C9CYP2C19NAMPTCYP3A4CYP2D6
SCHEMBL7103042 0.85 NAMPT (0.45) CYP2C9CYP2C19NAMPTCYP3A4CYP2D6
SCHEMBL7261276 0.83 CYP1A2 (0.53) CYP2C9CYP2C19NAMPTHDAC1HDAC3
SCHEMBL7262289 0.83 CYP1A2 (0.53) CYP2C9CYP2C19NAMPTHDAC1HDAC3
SCHEMBL7098726 0.83 CYP1A2 (0.53) CYP2C9CYP2C19NAMPTHDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120029036-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) 2012-02-02 US disclosed
EP-2394649-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029036-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF PLPBP, PYGL, QDPR CYP2C9 5/4885CYP2C19 26/4885NAMPT 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.